Boeing 737 MAX 10 Advances in FAA Testing as Certification Delays Continue 
Trump Weighs Blocking Exxon Investment as Venezuela Deemed “Uninvestable” 
FTC Blocks Edwards Lifesciences’ JenaValve Acquisition in Major Antitrust Ruling 
Rio Tinto–Glencore Talks Spark Pressure on BHP as Copper Fuels Mining Mega Deals 
xAI Cash Burn Highlights the High Cost of Competing in Generative AI 
Nvidia Appoints Former Google Executive Alison Wagonfeld as First Chief Marketing Officer 
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability 
EU Orders Elon Musk’s X to Preserve Grok AI Data Amid Probe Into Illegal Content 
Trump Considers Starlink to Restore Internet Access in Iran Amid Protests 
Anthropic Launches HIPAA-Compliant Healthcare Tools for Claude AI Amid Growing Competition 
Stellantis to End Plug-In Hybrid Sales in the U.S. as Demand Shifts Toward Traditional Hybrids 
China’s AI Sector Pushes to Close U.S. Tech Gap Amid Chipmaking Challenges 
Allegiant to Acquire Sun Country Airlines in $1.5 Billion Deal to Expand U.S. Leisure Travel Network 
OpenAI Sets $50 Billion Stock Grant Pool, Boosting Employee Equity and Valuation Outlook 
Hanwha Ocean Shares Rise on Plans to Expand U.S. Shipbuilding Capacity 
Aktis Oncology Prices Upsized IPO at $18, Raising $318 Million in Major Biotech Debut 
SOUTH SAN FRANCISCO, Calif., April 08, 2016 -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, today announced its participation at the 15th Annual Needham Healthcare Conference. William D. Waddill, Senior Vice President and Chief Financial Officer will present on Tuesday, April 12, 2016 at 3:00 p.m. Eastern Time at The Westin New York Grand Central Hotel in New York, NY.
About Calithera
Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. Calithera’s lead product candidate, CB-839, is currently being evaluated in three Phase 1 clinical trials in solid and hematological cancers. CB-1158 is a first-in- class immuno-oncology metabolic checkpoint inhibitor targeting arginase, a critical immunosuppressive enzyme responsible for T-cell suppression by myeloid-derived suppressor cells. Arginase depletes arginine, a nutrient that is critical for the activation, growth and survival of the body’s cancer-fighting immune cells, known as cytotoxic T -cells. Calithera is headquartered in South San Francisco, California. For more information about Calithera, please visit www.calithera.com.
Contact: Jennifer McNealey [email protected] 650-870-1071
